Patents by Inventor Janet Griffiths

Janet Griffiths has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CHRONIC RHINOSINUSITIS WITH ANTI-TSLP ANTIBODY
    Publication number: 20260226149
    Abstract: The present disclosure, relates, in general, to methods of treating chronic rhinosinusitis, with or without nasal polyps, using an antibody specific for thymic stromal lymphopoietin (TSLP).
    Type: Application
    Filed: February 2, 2024
    Publication date: August 6, 2026
    Inventor: Janet Griffiths
  • TREATMENT OF ASTHMA WITH ANTI-TSL P ANTIBODY
    Publication number: 20250032608
    Abstract: The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).
    Type: Application
    Filed: October 8, 2024
    Publication date: January 30, 2025
    Inventors: Jane R. Parnes, Janet Griffiths
  • TREATMENT OF ASTHMA WITH ANTI-TSLP ANTIBODY
    Publication number: 20210052726
    Abstract: The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).
    Type: Application
    Filed: November 9, 2020
    Publication date: February 25, 2021
    Inventors: Jane R. Parnes, Janet Griffiths
  • Treatment of asthma with anti-TSLP antibody
    Patent number: 10828365
    Abstract: The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: November 10, 2020
    Assignee: AMGEN INC.
    Inventors: Jane R. Parnes, Janet Griffiths
  • Treatment of Asthma With Anti-TSLP Antibody
    Publication number: 20180296669
    Abstract: The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).
    Type: Application
    Filed: April 12, 2018
    Publication date: October 18, 2018
    Inventors: Jane R. Parnes, Janet Griffiths